)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AcouSort
AcouSort (ACOU) investor relations material
AcouSort Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary26 Aug, 2026
Executive summary
Achieved 36% year-over-year net sales growth in Q2 2026, driven by new collaborations and product sales.
Expanded commercial activities with key installations and participation in major industry events in the US, Europe, and Asia.
Focused on diagnostics, cell therapy, and lab automation markets, leveraging OEM partnerships and research collaborations.
Financial highlights
Q2 2026 net sales: TSEK 2,116 (up from 1,551); H1 2026 net sales: TSEK 4,263 (up from 3,146) year-over-year.
Q2 2026 result before tax: TSEK -3,532 (Q2 2025: -2,809); H1 2026 result before tax: TSEK -5,901 (H1 2025: -6,831).
Equity ratio at June 30, 2026: 46% (down from 81%); cash and cash equivalents: TSEK 9,482.
Operating result for Q2 2026: TSEK -3,613 (Q2 2025: -2,487); H1 2026: TSEK -6,661 (H1 2025: -5,820).
Result per share H1 2026: SEK -0.28 (H1 2025: -0.41).
Outlook and guidance
Plans to solidify market positions in diagnostics, cell therapy, and lab automation through strategic partnerships.
Sufficient liquidity projected into Q1 2027, with ongoing efforts to secure additional institutional or strategic funding.
Continued focus on expanding OEM collaborations and advancing core technology.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AcouSort
- Q1 2026 saw higher sales, reduced losses, and solid funding through major royalty prepayments.ACOU
Q1 2026 - Net sales up 45% and equity ratio at 91%, with strong OEM-driven growth and secured funding.ACOUQ4 2025
- Improved financials and expanded OEM partnerships drive growth in diagnostics and cell therapy.ACOUQ3 2025
- Improved financials, strong cash, and new OEM partnerships position for future growth.ACOUQ2 2025
- Expanded collaborations and improved financials position AcouSort for continued growth.ACOUQ3 2024
- OEM collaborations and Werfen's launch drive AcouSort's strategic progress despite lower sales.ACOUQ2 2024
- Automated sample prep tech, OEM model, and strong partnerships drive growth and funding through 2026.ACOUStatus Update
- AcouSort advanced OEM partnerships and innovation, securing funding for continued growth.ACOUQ1 2025
- Losses narrowed and OEM partnerships expanded, with funding secured into Q3 2025.ACOUQ4 2024
Next AcouSort earnings date
Q3 202625 Nov, 2026
AcouSort
Next AcouSort earnings date
Q3 202625 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AcouSort is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, its products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing - so-called Point-of Care (POC) systems.